|
1
|
Krantz E, Trimpou P and Landin-Wilhelmsen
K: Effect of growth hormone treatment on fractures and quality of
life in postmenopausal osteoporosis: A 10-year follow-up study. J
Clin Endocrinol Metab. 100:3251–3259. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hansen KE, Nabak AC, Johnson RE,
Marvdashti S, Keuler NS, Shafer MM and Abrams SA: Isotope
concentrations from 24-h urine and 3-h serum samples can be used to
measure intestinal magnesium absorption in postmenopausal women. J
Nutr. 144:533–537. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sugimoto T, Nakamura T, Nakamura Y, Isogai
Y and Shiraki M: Profile of changes in bone turnover markers during
once-weekly teriparatide administration for 24 weeks in
postmenopausal women with osteoporosis. Osteoporos Int.
25:1173–1180. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bonnick S, De Villiers T, Odio A, Palacios
S, Chapurlat R, DaSilva C, Scott BB, Le Bailly De Tilleghem C,
Leung AT and Gurner D: Effects of odanacatib on BMD and safety in
the treatment of osteoporosis in postmenopausal women previously
treated with alendronate: A randomized placebo-controlled trial. J
Clin Endocrinol Metab. 98:4727–4735. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu HF, He HC, Yang L, Yang ZY, Yao K, Wu
YC, Yang XB and He CQ: Pulsed electromagnetic fields for
postmenopausal osteoporosis and concomitant lumbar osteoarthritis
in southwest China using proximal femur bone mineral density as the
primary endpoint: Study protocol for a randomized controlled trial.
Trials. 16:2652015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ruixo Pérez JJ, Zheng J and Mandema JW:
Similar relationship between the time course of bone mineral
density improvement and vertebral fracture risk reduction with
denosumab treatment in postmenopausal osteoporosis and prostate
cancer patients on androgen deprivation therapy. J Clin Pharmacol.
54:503–512. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stuss M, Rieske P, Cegłowska A,
Stêpień-Kłos W, Liberski PP, Brzeziańska E and Sewerynek E:
Assessment of OPG/RANK/RANKL gene expression levels in peripheral
blood mononuclear cells (PBMC) after treatment with strontium
ranelate and ibandronate in patients with postmenopausal
osteoporosis. J Clin Endocrinol Metab. 98:E1007–E1011. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bai P, Sun Y, Jin J, Hou J, Li R, Zhang Q
and Wang Y: Disturbance of the OPG/RANK/RANKL pathway and systemic
inflammation in COPD patients with emphysema and osteoporosis.
Respir Res. 12:1572011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Baek JM, Kim JY, Yoon KH, Oh J and Lee MS:
Ebselen is a potential anti-osteoporosis agent by suppressing
receptor activator of nuclear factor kappa-B ligand-induced
osteoclast differentiation in vitro and lipopolysaccharide-induced
inflammatory bone destruction in vivo. Int J Biol Sci. 12:478–488.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li H, Li T, Fan J, Li T, Fan L, Wang S,
Weng X, Han Q and Zhao RC: miR-216a rescues dexamethasone
suppression of osteogenesis, promotes osteoblast differentiation
and enhances bone formation, by regulating c-Cbl-mediated PI3K/AKT
pathway. Cell Death Differ. 22:1935–1945. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yuan FL, Xu RS, Jiang DL, He XL, Su Q, Jin
C and Li X: Leonurine hydrochloride inhibits osteoclastogenesis and
prevents osteoporosis associated with estrogen deficiency by
inhibiting the NF-κB and PI3K/Akt signaling pathways. Bone.
75:128–137. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hao L, Fu J, Tian Y and Wu J: Systematic
analysis of lncRNAs, miRNAs and mRNAs for the identification of
biomarkers for osteoporosis in the mandible of ovariectomized mice.
Int J Mol Med. 40:689–702. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen J, Qiu M, Dou C, Cao Z and Dong S:
MicroRNAs in bone balance and osteoporosis. Drug Dev Res.
76:235–245. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li H, Wang Z, Fu Q and Zhang J: Plasma
miRNA levels correlate with sensitivity to bone mineral density in
postmenopausal osteoporosis patients. Biomarkers. 19:553–556. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brixen K, Chapurlat R, Cheung AM, Keaveny
TM, Fuerst T, Engelke K, Recker R, Dardzinski B, Verbruggen N,
Ather S, et al: Bone density, turnover, and estimated strength in
postmenopausal women treated with odanacatib: A randomized trial. J
Clin Endocrinol Metab. 98:571–580. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Binkley N, Bolognese M,
Sidorowicz-Bialynicka A, Vally T, Trout R, Miller C, Buben CE,
Gilligan JP and Krause DS: Oral Calcitonin in Postmenopausal
Osteoporosis (ORACAL) Investigators: A phase 3 trial of the
efficacy and safety of oral recombinant calcitonin: The Oral
Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial. J Bone
Miner Res. 27:1821–1829. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ma Y, Shan Z, Ma J, Wang Q, Chu J, Xu P,
Qin A and Fan S: Validation of downregulated microRNAs during
osteoclast formation and osteoporosis progression. Mol Med Rep.
13:2273–2280. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jiang ZS and Hao ZH: An insertion/deletion
polymorphism within the 3′-untranslated region of COL1A2 confers
susceptibility to osteoporosis. Mol Med Rep. 14:4415–4421. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang D, Maalouf NM, Adams-Huet B, Moe OW
and Sakhaee K: Effects of sex and postmenopausal estrogen use on
serum phosphorus levels: A cross-sectional study of the National
Health and Nutrition Examination Survey (NHANES) 2003–2006. Am J
Kidney Dis. 63:198–205. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Martynetz FA, Pessole Biondo-Simões Mde L,
Martynetz JR, Martynetz TD, Zimerman E and Neto HM: Tomografic and
tensiometric assessment on femurs from oophorectomized rats
subjected to hormone replacement therapy. Rev Bras Ortop. 45:40–45.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sanders S and Geraci SA: Osteoporosis in
postmenopausal women: Considerations in prevention and treatment:
(women's health series). South Med J. 106:698–706. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ma F, Feng Y, Li W, Li Z, Liu T and Li L:
miR-148a suppresses estrogen-induced viability and migration of
breast cancer cells via inhibition of estrogen receptor α
expression. Exp Ther Med. 13:2515–2522. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang H, Wang Y, Xu T, Li C, Wu J, He Q,
Wang G, Ding C, Liu K, Tang H and Ji F: Increased expression of
microRNA-148a in osteosarcoma promotes cancer cell growth by
targeting PTEN. Oncol Lett. 12:3208–3214. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ge P, Cui Y, Liu F, Luan J, Zhou X and Han
J: L-carnitine affects osteoblast differentiation in NIH3T3
fibroblasts by the IGF-1/PI3K/Akt signalling pathway. Biosci
Trends. 9:42–48. 2015. View Article : Google Scholar : PubMed/NCBI
|
